Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.32 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.31 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22873686 | 0.93 | LRRK2 (0.37) | LRRK2 | |
| SCHEMBL22753154 | 0.93 | LRRK2 (0.47) | LRRK2PDE10AABCG2 | |
| SCHEMBL22873794 | 0.84 | LRRK2 (0.41) | LRRK2 | |
| SCHEMBL20437654 | 0.84 | LRRK2 (0.35) | LRRK2 | |
| SCHEMBL22873752 | 0.81 | LRRK2 (0.35) | LRRK2 | |
| SCHEMBL20438237 | 0.80 | LRRK2 (0.36) | LRRK2ABCG2 | |
| SCHEMBL22753222 | 0.80 | LRRK2 (0.36) | LRRK2ABCG2 | |
| SCHEMBL22753211 | 0.80 | LRRK2 (0.36) | LRRK2PDE10A | |
| SCHEMBL20443767 | 0.80 | LRRK2 (0.48) | LRRK2 | |
| SCHEMBL22753236 | 0.79 | LRRK2 (0.33) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3325449-B1 | HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | LRRK2, PARK7, PINK1 | LRRK2 1/4885PDE10A 2164/4885ACVR2A 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.